Search

Author/Creator Halilovic, E.

1. Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors. (December 2016)

Authors:
Hyman, D.; Chatterjee, M.; Langenberg, M.H.G.; Lin, C.C.; Suárez, C.; Tai, D.; Cassier, P.; Yamamoto, N.; De Weger, V.A.; Jeay, S.; Meille, C.; Halilovic, E.; Mariconti, L.; Guerreiro, N.; Kumar, A.; Wuerthner, J.U.; Bauer, S.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S128
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. (December 2016)

Authors:
Carita, G.; Frisch-Dit-Leitz, E.; Dahmani, A.; Raymondie, C.; Cassoux, N.; Piperno-Neumann, S.; Némati, F.; Laurent, C.; De Koning, L.; Halilovic, E.; Jeay, S.; Wylie, A.; Emery, C.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S31
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search